UK Agency Tests Remote Inspections Program To Identify At-Risk GDP Sites
The UK Medicines and Healthcare products Regulatory Agency is testing a new remote, office-based inspection process, in place of physical inspections, to assess risk at “satellite sites” that perform a limited number of good distribution practice-related activities for companies.
You may also be interested in...
The UK’s Medicines and Healthcare products Regulatory Agency is replacing all non-essential on-site inspections with office-based assessments due to the coronavirus pandemic. The agency also plans to rely on information from international regulatory partners to maintain oversight.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.